Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd

Medifocus Inc. Announces Its Sponsorship at the VM Medical 20th Anniversary Breast Cancer Conference October 23rd and 24th:
Poster Presentation Outlining the Pivotal Phase III Clinical Study Currently Being Investigated at VM Medical, the Largest Non Public Private Breast Center in Canada

COLUMBIA, Md. and Toronto, ON- October 23, 2014 Medifocus, Inc. (OTCQX: MDFZF and TSXV: MFS) (Medifocus or the Company), is pleased to announce that it will be a sponsor at the upcoming VM Medical 20th Anniversary Breast Cancer Conference held on October 23rd and 24th, 2014 in Montreal, Canada. In addition, Medifocus will present a Poster on its “Wide-Field Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-based Chemotherapy to Increase Local Response for Improved Breast Conservation Potential. The Pivotal Phase III breast cancer treatment study has been approved by both the USA Food and Drug Administration and also the Canadian Bureau of Medical Devices (BMD). Dr. John R. Keyserlingk, MD, is the Principal Investigator in Canada at the VM Med (Ville Marie Medical Center) in Montreal, Canada. The USA Principal Investigational site has already been initiated at the University of Oklahoma Breast Institute under the supervision of our USA Principal Investigator, Dr. William C. Dooley, MD. The goal of the 238-patient Medifocus-sponsored randomized Phase III study is to demonstrate that preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) thus reducing the need of a mastectomy. Further details of the Medifocus, Inc. Pivotal Phase III study are published on the href=””> web site. The Medifocus, Inc. APA-1000 system used in this clinical trial is based on focused microwave thermotherapy technology exclusively licensed from the Massachusetts Institute of Technology (MIT).

Dr. Augustine Y. Cheung, President and CEO, stated, “We are very pleased to be part of this breast cancer conference. We are taking steps to refocus our resources so that Medifocus will become a Total Breast Disease Management Company. We firmly believe that the progress we have been making in our breast cancer clinical trials will ultimately be reflected in increased shareholder value.”

About Medifocus, Inc.:

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drugs Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus’ APA 1000 Breast Cancer
Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers.

Please visit, and for more details.

Forward-Looking Statements

This news release contains “forward-looking statements” and “forward-looking information”, which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect to the benefit to Medifocus’ future growth resulting from the acquisition of additional intellectual property rights, additional treatment possibilities and the expectation that sales from Prolieve® may accelerate as a consequence. Forward-looking statements are frequently characterized by words such as “plan,” “expect,” “project,” “intend,” “believe,” “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, the Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Relations: John Mon, COO, Medifocus, Inc. Tel: 410-290-5734